Assistant Professor Christopher R. Ensor, PharmD, BCPS-CV is the co-primary investigator, along with his colleague John McDyer, MD, who recently received an investigator-sponsored trial grant from Amgen to investigate the novel proteasome inhibitor Carfilzomib in lung transplant recipients with Antibody Mediated Rejection (AMR) in an open label phase II active treatment only study. Antibody-mediated rejection (AMR) is a significant cause of morbidity and mortality in lung transplant recipients and can lead to the development of chronic rejection. The team will also investigate the novel mechanisms by which Carfilzomib acts on human immune cells. They anticipate that Carfilzomib-based therapy will decrease circulating antibodies against the transplanted lungs and improve lung function over time.
Assistant Professor Christopher R. Ensor, PharmD, BCPS-CV is the co-primary investigator, along with his colleague John McDyer, MD, who recently received an investigator-sponsored trial grant from Amgen to investigate the novel proteasome inhibitor Carfilzomib in lung transplant recipients with Antibody Mediated Rejection (AMR) in an open label phase II active treatment only study. Antibody-mediated rejection (AMR) is a significant cause of morbidity and mortality in lung transplant recipients and can lead to the development of chronic rejection. The team will also investigate the novel mechanisms by which Carfilzomib acts on human immune cells. They anticipate that Carfilzomib-based therapy will decrease circulating antibodies against the transplanted lungs and improve lung function over time.
